University of Las Palmas de Gran Canaria Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Las Palmas de G.C. Spain (1965)

Organization Overview

First Clinical Trial
2007
NCT01078818
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Canarias University | Canarias University Hospital | COMPLEJO HOSPITALARIO UNIVERSITARIO DE CANARIAS | Complejo Hospitalario Universitario Insular Materno Infantil | Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas, Spain | Dr. Negrín University Hospital, Las Palmas, Spain | Gutiérrez-Hernández, ME | Hospital Insular de las Palmas | Hospital La Paloma Las Palmas de Gran Canaria | Hospital Univer. Materno-Infantil de Canarias ( Las Palmas de Gran Canaria) | Hospital Universitario de Canarias | Hospital Universitario de Canarias. La Laguna | Hospital Universitario de Canarias. La Laguna. Tenerife. Spain | Hospital Universitario de Gran Canaria | Hospital Universitario Insular de Canarias | Hospital Universitario Materno-Infantil de Canarias, Las Palmas de Gran Canaria | Hosptial Dr. Negrin de Las Palmas de Gran Canaria | Institute for Applied Microelectronics, University of Las Palmas de G. C., Spain | Las Palmas Medical Center | University of Las Palmas de G. C. | University of Las Palmas de Gran Canaria

Active Ingredients

Drugs in Phase 4 Trials (11)

aflibercept (zaltrap) (1 trial)

calcifediol (1 trial)

cetearyl alcohol (1 trial)

ferrous fumarate (1 trial)

iron sucrose (venofer) (1 trial)

ivabradine (corlanor) (1 trial)

levosimendan (3 trials)

paricalcitol (zemplar) (1 trial)

pentoxifylline (trental) (2 trials)

polyethylene glycol (3 trials)

vitamin c (3 trials)

Drugs in Phase 3 Trials (6)

anastrozole (arimidex) (1 trial)

bevacizumab (avastin) (1 trial)

fulvestrant (faslodex) (1 trial)

oxygen (3 trials)

ozone (2 trials)

triamcinolone (kenalog) (1 trial)

Drugs in Phase 2 Trials (19)

bendamustine (treanda) (3 trials)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

enzalutamide (xtandi) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

is-001 (1 trial)

isphagula husk (1 trial)

leucovorin (1 trial)

mitoxantrone (novantrone) (1 trial)

oxaliplatin (eloxatin) (2 trials)

panitumumab (vectibix) (1 trial)

pazopanib (votrient) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (4 trials)

trabectedin (yondelis) (1 trial)

urea (2 trials)

vincristine (oncovin) (1 trial)

vitamin e (1 trial)

Drugs in Other Trials (19)

boceprevir (victrelis) (2 trials)

ciprofloxacin (cipro) (1 trial)

clavulanate (Augmentin) (1 trial)

daclatasvir (daklinza) (1 trial)

dasabuvir (Exviera) (2 trials)

elbasvir (2 trials)

grazoprevir (zepatier) (2 trials)

ledipasvir (Harvoni) (2 trials)

ombitasvir (Viekira Pak) (1 trial)

paritaprevir (viekira pak) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

propofol (diprivan) (1 trial)

ritonavir (Norvir) (1 trial)

simeprevir (olysio) (2 trials)

sofosbuvir (sovaldi) (2 trials)

sulfamethoxazole (gantanol) (1 trial)

telaprevir (incivek) (2 trials)

trimethoprim (1 trial)

velpatasvir (Epclusa) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Aggression (Phase 2)

Anemia (Phase 4)

Breast Neoplasms (Phase 3)

Chondrosarcoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 3)

Edema (Phase 3)

Fibrosis (Phase 2)

Heart Diseases (Phase 3)

Heart Failure (Phase 4)

Infarction (Phase 3)

Irritable Bowel Syndrome (Phase 4)

Ischemia (Phase 3)

Kidney Failure, Chronic (Phase 4)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Macular Degeneration (Phase 4)

Macular Edema (Phase 3)

Metabolic Syndrome (Phase 2)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Neoplasms, Fibrous Tissue (Phase 2)

Neuralgia (Phase 3)

Peripheral Nervous System Diseases (Phase 3)

Prostatic Neoplasms (Phase 2)

Renal Insufficiency (Phase 4)

Solitary Fibrous Tumors (Phase 2)

ST Elevation Myocardial Infarction (Phase 3)

Syndrome (Phase 4)

Wet Macular Degeneration (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial APIs: 55